The clinical and public health problem of relapse despite primaquine therapy: Case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Joan Ingram, R H ^a   Crenna Darusallam, Chelzie ^b   Soebianto, Saraswati ^c   Noviyanti, Rintis ^d   Kevin Baird, J ^c,d  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

^c OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Compliance; CYP2D6 polymorphism; Plasmodium vivax; Primaquine; Relapse; Resistance; Therapeutic failure; Tolerance

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; ARTEMISIA ANNUA EXTRACT; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CYTOCHROME P450 2D6; DOXYCYCLINE; PRIMAQUINE; ANTIMALARIAL AGENT;

ADULT; CASE REPORT; CAUCASIAN; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENE DELETION; GENOTYPE; HEADACHE; HUMAN; MALAISE; MALARIA FALCIPARUM; NEW ZEALAND; PAPUA NEW GUINEA; PHENOTYPE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; RELAPSE; REVIEW; RIGOR; TROPHOZOITE; MALARIA, VIVAX; MIDDLE AGED; RECURRENT DISEASE; TRAVEL; TREATMENT OUTCOME;

ANTIMALARIALS; DOXYCYCLINE; FEMALE; HUMANS; MALARIA, VIVAX; MIDDLE AGED; NEW ZEALAND; PAPUA NEW GUINEA; PRIMAQUINE; RECURRENCE; TRAVEL; TREATMENT OUTCOME;

EID: 85051837414     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-488     Document Type: Review

References (38)

1. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HF, Price RN, Mueller I, Baird JK, Hay SI: A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis 2012, 6:e1814.
2. Hwang J, Cullen KA, Kachur SP, Arguin PM, Baird JK: Severe morbidity and mortality risk from malaria in the United States, 1985-2011. Infect Dis 2014, 1:1.
3. Smith AD, Bradely DJ, Smith V, Blaze M, Behrens RH, Chiodini PL, Whitty CJ: Imported malaria and high risk groups: observational study using UK surveillance data. Brit Med J 2008, 337:a120.
4. White NJ: Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J 2011, 10:297.
5. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, Van Boeckel TP, Messina JP, Shanks GD, Smith DL, Baird JK, Hay SI: Geographical variation in Plasmodium vivax relapse. Malar J 2014, 13:144.
6. Eyles DE, Young MD: Studies on imported malarias. 7. The parasitological pattern of relapsing Plasmodium vivax in military patients. J Nat Malar Soc 1948, 7:23-37.
7. Baird JK: Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev 2013, 26:36-57.
8. Anstey NM, Douglas NM, Pospoprodjo JR, Price RN: Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol 2012, 80:151-201.
9. Manning L, Laman M, Law I, Bona C, Aipit S, Teine D, Warrell J, Rosanas-Urgell A, Lin E, Kiniboro B, Vince J, Hwaiwhanje I, Karunajeewa H, Michon P, Siba P, Mueller I, Davis TM: Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One 2011, 6:e29203.
10. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, Lampah DA, Price RN: Multi-drug resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 2008, 5:e128.
11. Quispe AM, Pozo E, Guerrero E, Durand S, Baldeviano GC, Edgel KA, Graf PC, Lescano AG: Plasmodium vivax hospitalizations in a monoendemic malaria region: severe vivax malaria? Am J Trop Med Hyg 2014, 91:11-17.
12. Kotwal RS, Wenzel RB, Sterling RA, Porter WD, Jordan NN, Petrucelli BP: An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 2005, 293:212-216.
13. Baird JK, Hoffman SL: Primaquine therapy for malaria. Clin Infect Dis 2004, 39:1336-1345.
14. Hill DR, Baird JK, Parise ME, Lewis LS, Ryan ET, Magill AJ: Primaquine: a report from the CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006, 75:402-415.
15. Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MA, Suwonkerd W: Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J Health Popul Nutr 2009, 27:4-13.
16. Baird JK: Reinventing primaquine for endemic malaria. Expert Opin Emerg Dis 2012, 42:1049-1054.
17. Baird J: Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob Agents Chemother 2011, 55:1827-1830.
18. WHO: Guidelines for the Treatment of Malaria. 2nd edition. Geneva: World Health Organization; 2010:194.
19. Rijken MJ, McGready R, Boel E, Poespoprodjo R, Singh N, Syafruddin D, Rogerson S, Nosten F: Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis 2012, 12:75-88.
20. Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, McGready R, Sugiarto P, Tjitra E, Anstey NM, Price RN: Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis 2008, 46:1374-1381.
21. Singh B, Bobogare A, Cox-Singh J, Snounou G, Abdullah MS, Rahman HA: A genus and species specific nested polymerase chain reaction malaria detection assay for epidemiologic studies. Am J Trop Med Hyg 1999, 60:687-692.
22. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part 1. Clin Pharmacokinet 2009, 48:689-723.
23. Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A: Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at gobal and microgeographic scales. Pharmacogen Genom 2009, 19:170-179.
24. Microsomes containing metabolizer phenotype-specific CYP2D6 isozyme. http://www.xenotechllc.com/products/subcellular-fractions/human/liver/genotyped/cyp2d6.
25. Jurica J, Bartecek R, Zourkova A, Pindurova E, Sulcova A, Kasparek T, Zendulka O: Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice. J Clin Pharm Ther 2012, 37:486-490.
26. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, Deye G, Melendez V, Ockenhouse CF: Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med 2013, 369:1381-1382.
27. Ehrman FC, Ellis JM, Young MD: Plasmodium vivax Chesson strain. Science 1945, 101:377.
28. Young MD, Eyles DE, Burgess RW: Studies on imported malaria. 10. An evaluation of the foreign malarias introduced in the United States by returning troops. J Nat Malar Soc 1948, 7:171-185.
29. Edgecomb JH, Arnold J, Yount EH Jr, Alving AS, Eichelberger L: Primaquine, SN 13272: a new curative agent in vivax malaria. A preliminary report. J Nat Malar Soc 1950, 9:285-292.
30. Zanger UM, Raimundo S, Echelbaum M: Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:23-37.
31. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, Caridha D, Zeng Q, Reichard GA, Ockenhouse C, Bennett J, Walker LA, Ohrt C, Melendez V: The metabolism of primaquine to its active metabolite is dependent on CYP2D6. Malar J 2013, 12:212.
32. Vasquez-Vivar J, Augusto O: Hydroxylated metabolites of the antimalarial drug primaquine. J Biol Chem 1992, 267:6848-6854.
33. Schmidt LH, Fradkin R, Vaughan D, Rasco J: Radical cure of infections with Plasmodium cynomolgi: a function of total 8-aminoquinoline dose. Am J Trop Med Hyg 1977, 26:1116-1128.
34. Alving AS, Johnson CF, Tarlov AR, Brewer GJ, Kellermeyer RW, Carson PE: Mitigation of the hemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Plasmodium vivax by intermittent regimens of drug administration. Bull World Health Organ 1960, 22:621-631.
35. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ: Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 2014, 14:982-991. in press.
36. Baird JK: Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 2009, 22:508-534.
37. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, Price RN: Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J 2012, 11:280.
38. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, Setiabudy R, Nurleila S, Ekawati LL, Elyazar I, Farrar J, Sudoyo H, Baird JK: Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother 2013, 57:1128-1135.